A phase II trial with cabozantinib in patients with metastatic colorectal cancer, after previous treatment (mCRC).
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2538920
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: To determine the anti-tumour activity of cabozantinib (evaluated as the number of patients that are free of progression at 16 weeks since the start of treatment) in chemorefractory patients with mCRC, after progression from =2 lines of treatment.
Primary endpoints: Progression Free Survival (PFS) rate at 16 weeks: the rate of patients who have not experienced disease progression or death for any cause at 16 weeks.
创建时间：
2019-07-15
